Key clinical point: Patients with previous, but not current, severe clinical asthma exacerbations may still use their rescue inhalers daily and therefore require additional therapy.
Major finding: Patients who did not have exacerbations during the study period used the ProAir Digihaler an average of 1.14 times per day.
Study details: Phase 3 study of 360 patients.
Disclosures: The study was sponsored by Teva, makers of the ProAir Digihaler. Dr. Pleasants disclosed relationships with Teva, Grifols, Sunovion, and Boehringer Ingelheim.
Pleasants R et al. CHEST 2019. Abstract, doi: 10.1016/j.chest.2019.08.273.